On 5/26/2022 Roth Capital brokerage Lowered the Price Target for First Wave BioPharma, Inc. (FWBI) from $600.00 to $270.00 giving a Buy Rating for the stock! The stock is now at a historic low: $3.31. In January 2021 it was $788. Just to reach the Analyst Price Target, it need to grow 81.5X from this level. The Market cap is extremely low: 4.58 Mil. 81X would...
First Wave BioPharma is a clinical-stage biopharmaceutical company that specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases. 52 Week Range 1.27 - 26.30 Now the price is close to all time low and looks like a buy opportunity!
James Sapirstein Chairman, President and CEO of First Wave BioPharma, Inc.: "We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative...